Relationship of the type of bcr-abl hybrid mRNA to clinical course and transforming activity in Philadelphia-positive chronic myelogenous leukemia.
We studied the type of bcr-abl mRNA for 34 patients with chronic myelogenous leukemia and analyzed for correlations among the mRNA type, the clinical outcome and the transforming activity using the tumorigenicity assay. There was no difference in the distribution of the mRNA-types (b2-a2 and b3-a2) between clinical phases. We found no correlation between the two types of bcr-abl mRNA and the chronic phase duration or survival. The DNA from 12 of 20 chronic phase patients and all five blastic phase patients showed transforming activity. Although there was no difference in the positive rate of transforming activity among the two mRNA-type groups, the blastic phase patients showed a tendency to have higher transforming activity.
Futaki
M
M
Third Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Inokuchi
K
K
Matsuoka
H
H
Miyake
K
K
Dan
K
K
Nomura
T
T
D016475:3T3 Cells; D000328:Adult; D000368:Aged; D000818:Animals; D001483:Base Sequence; D002471:Cell Transformation, Neoplastic; D005260:Female; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics* / Q000401:mortality; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D008969:Molecular Sequence Data; D011379:Prognosis; D012333:RNA, Messenger
D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl